Treatment Effectiveness
User reported effectiveness ratings Imipramine for various conditions.
| Conditions | Major Improvement | Moderate Improvement | Much Worse | No Effect | Worse | Responses |
|---|---|---|---|---|---|---|
| Back Pain | 8% | 15% | 15% | 54% | 8% | 13 |
| Depression | 6% | 22% | 16% | 46% | 10% | 50 |
| Mitral Valve Prolapse | 20% | 20% | 20% | 30% | 10% | 10 |
| Vulvodynia | 11% | 26% | 0% | 53% | 11% | 19 |
| Anxiety | 5% | 23% | 16% | 33% | 23% | 43 |
Side Effects
User-reported side effects of Imipramine
| Side Effect | Percent of Reports Imipramine |
|---|---|
| Constipation | 36% |
| Dry Mouth | 64% |
| Blurred Vision | 20% |
| Changes in Appetite or Weight | 25% |
| Changes in Sex Drive or Ability | 18% |
| Difficulty Urinating | 12% |
| Drowsiness | 47% |
| Excessive Sweating | 33% |
| Excitement or Anxiety | 27% |
| Frequent Urination | 10% |
| Nightmares | 12% |
| Skin More Sensitive to Sunlight Than Usual | 18% |
| Weakness or Tiredness | 45% |
| Nausea | 20% |
Outcomes
Below is the degree of change seen after Imipramine is higher than average.
|
|
Outcomes Label
Imipramine Info
| Property | Value |
|---|---|
| Variable Name | Imipramine |
| Aggregation Method | SUM |
| Analysis Performed At | 2020-05-06 |
| Duration of Action | 21 days |
| Filling Value | 0 |
| Minimum Allowed Value | 0 count |
| Number of Aggregate Predictors | 0 |
| Number of Aggregate Outcomes | 0 |
| Number of Measurements | 0 |
| Number of Measurements (including those generated by tagged, joined, or child variables) | 0 |
| Public | true |
| Onset Delay | 30 minutes |
| Unit | Count |
| User Variables | 0 |
| Variable Category | Treatments |
| Variable ID | 93940 |